Textbook of Medical OncologyStan B. Kaye`, Stan B Kaye Effective care of the cancer patient increasingly involves systemic treatment, and as the range of available therapeutic agents continues to expand, the medical oncologist must be fully aware of the rationale for choosing specific drugs and combinations. Already acclaimed in previous editions as a key source of reference for all working in the field of Oncology, the third edition of this text has now been completely revised with important new chapters and illustrations throughout to keep it at the forefront of cancer medicine. Short Contents |
Contents
Principles of systemic therapy | 48 |
Principles and examples of systemic | 54 |
51 | 301 |
35 | 312 |
Principles of clinical trials | 320 |
Gynecologic cancer | 350 |
9 | 382 |
Ian Chau and David Cunningham | 404 |
Ronald de Wit and Cora N Sternberg | 413 |
Cristiana Sessa and Silvia Marsoni | 427 |
| 497 | |
| 520 | |
Common terms and phrases
activity acute adjuvant chemotherapy agents antibody assessment associated B-cell biopsy blood bolus bone marrow breast cancer cancer patients carboplatin chemoradiation chromosome cisplatin Clin Oncol 2003 clinical trials colorectal combination compared cycles cyclophosphamide cytotoxic diagnosis docetaxel dose doxorubicin drug effect efficacy Engl etoposide evaluation fluorouracil gemcitabine gene genetic gliomas Group growth factor head and neck high-dose histological hormone improve increased infusion inhibition inhibitors irinotecan kinase lesions leukemia liver lung cancer lymph nodes lymphoma malignant markers melanoma metastases mg/m² molecular mutations neutropenia Oncology opioid ovarian cancer overall survival oxaliplatin paclitaxel pain patients with advanced phase II trials plasma preoperative primary tumor prognostic factors prostate protein radiation therapy radiotherapy randomized studies randomized trials receptor recurrence regimen relapse renal resection response rate risk rituximab sarcomas stage surgery surgical symptoms syndrome tamoxifen target therapeutic tion tissue toxicity transplantation treated treatment tumor cells unknown primary versus weeks